NCT07360093

Brief Summary

The primary aim of this study is to prospectively compare the effects of the pericapsular nerve group (PENG) block alone and the combination of PENG block with pulsed radiofrequency (PRF) on pain intensity in patients with chronic hip pain. As a secondary aim, the effects of both treatment modalities on hip function are intended to be evaluated using valid and reliable functional assessment scales. Through this study, it is aimed to demonstrate the clinical contribution of adding PRF to the PENG block and to identify a more effective and longer-lasting approach for the interventional treatment of chronic hip pain.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
84

participants targeted

Target at P50-P75 for all trials

Timeline
10mo left

Started Feb 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress24%
Feb 2026Feb 2027

First Submitted

Initial submission to the registry

January 14, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 22, 2026

Completed
10 days until next milestone

Study Start

First participant enrolled

February 1, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2027

Expected
27 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2027

Last Updated

March 18, 2026

Status Verified

March 1, 2026

Enrollment Period

1 year

First QC Date

January 14, 2026

Last Update Submit

March 15, 2026

Conditions

Keywords

Osteoarthritis, Hip,Pain, ChronicNerve BlockadePulsed Radiofrequency Treatment

Outcome Measures

Primary Outcomes (1)

  • Change in pain intensity measured by the Visual Analog Scale (VAS, 0-10; higher scores indicate worse pain)

    Pain intensity will be assessed using the Visual Analog Scale (VAS), a validated pain measurement tool ranging from 0 to 10, where 0 indicates no pain and 10 represents the worst pain imaginable.

    baseline (pre-procedure) and at 1 week, 1 month, 3 months, and 6 months after the procedure.

Secondary Outcomes (3)

  • Change in Pain, Stiffness, and Physical Function Measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, 0-96)

    baseline (pre-procedure) and at 1 week, 1 month, 3 months, and 6 months after the procedure.

  • Change in Hip Function Measured by the Harris Hip Score (HHS, 0-100)

    Baseline (pre-procedure), 1 week, 1 month (primary functional endpoint), 3 months, and 6 months after pulsed radiofrequency (PRF) treatment.

  • Secondary Outcome: TAnalgesic Use

    Baseline and at 1 week, 1 month, 3 months, and 6 months post-intervention

Study Arms (1)

Group PENG

The initial step in patients diagnosed with chronic hip pain is a diagnostic intervention, namely the application of a pericapsular nerve group (PENG) block. In patients who benefit from the diagnostic block-defined as a reduction of 50% or more in VAS scores following the procedure-pulsed radiofrequency (PRF) treatment is added as a second-stage intervention. This stepwise approach reflects standard clinical practice, and both procedures are commonly used in clinical praqctice for the management of chronic hip pain. However, the available evidence in the literature on this approach is largely limited to case reports and retrospective case series. The aim of the present study is to document and share the clinical outcomes of this treatment strategy routinely applied in clinical practice.

Procedure: PENG Block Pulsed radiofrequency

Interventions

This intervention consists of a stepwise, two-stage treatment protocol routinely applied in our clinical practice for the management of chronic hip pain. In the first stage, all patients undergo an ultrasound-guided pericapsular nerve group (PENG) block as a diagnostic and therapeutic procedure. Pain intensity is assessed using the Visual Analog Scale (VAS) following the diagnostic block. Only patients who demonstrate a clinically meaningful response, defined as a reduction of 50% or greater in VAS scores, proceed to the second stage of the intervention. In the second stage, pulsed radiofrequency (PRF) treatment is applied to the same target region in addition to the PENG block, aiming to achieve longer-lasting analgesia through neuromodulation without tissue destruction.

Group PENG

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

18-80 years old with chronical hip pain

You may qualify if:

  • Presence of chronic hip pain lasting at least 3 months
  • Baseline Visual Analog Scale (VAS) score ≥ 4
  • Clinical and/or radiological diagnosis of hip osteoarthritis
  • Inadequate response to conservative treatments

You may not qualify if:

  • Local or systemic infection at the intervention site
  • Coagulopathy or inability to discontinue anticoagulant therapy
  • Hip pain related to malignancy
  • History of previous hip arthroplasty
  • Severe neurological deficit
  • Pregnancy or breastfeeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara Bilkent City Hospital

Ankara, 06680, Turkey (Türkiye)

RECRUITING

Related Publications (2)

  • Jadon A. Pulsed Radiofrequency (PRF) of Pericapsular Nerves Group (PENG) in Chronic Hip Pain-A Case Report. Turk J Anaesthesiol Reanim. 2021 Dec;49(6):490-493. doi: 10.5152/TJAR.2021.1080. PMID: 35110031; PMCID: PMC9472694.

    BACKGROUND
  • 10.5152/TJAR.2021.21230

    BACKGROUND

MeSH Terms

Conditions

OsteoarthritisOsteoarthritis, HipChronic Pain

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Ulku Sabuncu MD, Assoc. prof.

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc. Prof.

Study Record Dates

First Submitted

January 14, 2026

First Posted

January 22, 2026

Study Start

February 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 28, 2027

Last Updated

March 18, 2026

Record last verified: 2026-03

Locations